series-c-plus
Stage
2015
Founded
1
Investors
About
Asceneuron is a clinical-stage biotechnology company developing novel orally available therapeutics for neurodegenerative diseases. Their lead compound, ASN90, is an O-GlcNAcase inhibitor currently in clinical development for Multiple System Atrophy.
Explore Asceneuron's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.